CRISPR Therapeutics Stock (NASDAQ: CRSP)
|Day Range61.26 - 64.19||52 Wk Range42.51 - 86.95||Open / Close63.88 / 61.65||Float / Outstanding67.4M / 78M|
|Vol / Avg.775.4K / 1.4M||Mkt Cap4.8B||P/E-||50d Avg. Price70.05|
|Div / Yield-||Payout Ratio-||Total Float67.4M||EPS-2.4|
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of CRISPR Therapeutics (NASDAQ: CRSP) through any online brokerage.
There are no as such competitors for CRISPR Therapeutics.
The latest price target for CRISPR Therapeutics (NASDAQ: CRSP) was reported by Credit Suisse on Tuesday, August 9, 2022. The analyst firm set a price target for 90.00 expecting CRSP to rise to within 12 months (a possible 45.99% upside). 32 analyst firms have reported ratings in the last year.
The stock price for CRISPR Therapeutics (NASDAQ: CRSP) is $61.65 last updated Today at October 7, 2022, 8:00 PM UTC.
There are no upcoming dividends for CRISPR Therapeutics.
CRISPR Therapeutics’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for CRISPR Therapeutics.
CRISPR Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.